Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression

Jeffrey R. Vittengl, Robin B. Jarrett, Erica Weitz, Steven D. Hollon, Jos Twisk, Ioana Cristea, Daniel David, Robert J. DeRubeis, Sona Dimidjian, Boadie W. Dunlop, Mahbobeh Faramarzi, Ulrich Hegerl, Sidney H. Kennedy, Farzan Kheirkhah, Roland Mergl, Jeanne Miranda, David C. Mohr, A. John Rush, Zindel V. Segal, Juned Siddique & 2 others Anne D. Simons, Pim Cuijpers

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: Although the average depressed patient benefits moderately from cognitive-behavioral therapy (CBT) or pharmacotherapy, some experience divergent outcomes. The authors tested frequencies, predictors, and moderators of negative and unusually positive outcomes. Method: Sixteen randomized clinical trials comparing CBT and pharmacotherapy for unipolar depression in 1,700 patients provided individual pre- and posttreatment scores on the Hamilton Depression Rating Scale (HAM-D) and/or Beck Depression Inventory (BDI). The authors examined demographic and clinical predictors and treatmentmoderators of any deterioration (increase≥1HAM-Dor BDI point), reliable deterioration (increase ≥8 HAM-D or ≥9 BDI points), extreme nonresponse (posttreatment HAM-D score ≥21 or BDI score ≥31), superior improvement (HAM-D or BDI decrease≥ 95%), and superior response (posttreatmentHAM-D or BDI score of 0) using multilevel models. Results: About5%27%of patients showedany deterioration, 1% reliable deterioration, 4%25% extreme nonresponse, 6%210% superior improvement, and 4%25% superior response. Superior improvement on the HAM-D only (odds ratio=1.67) and attrition (odds ratio=1.67) were more frequent in pharmacotherapy than in CBT. Patients with deterioration or superior response had lower pretreatment symptom levels, whereas patients with extreme nonresponse or superior improvement had higher levels. Conclusions: Deterioration and extreme nonresponse and, similarly, superior improvement and superior response, both occur infrequently in randomized clinical trials comparing CBT and pharmacotherapy for depression. Pretreatment symptom levels help forecast negative and unusually positive outcomes but do not guide selection of CBT versus pharmacotherapy. Pharmacotherapy may produce clinician-rated superior improvement and attrition more frequently than does CBT.

Original languageEnglish (US)
Pages (from-to)481-490
Number of pages10
JournalAmerican Journal of Psychiatry
Volume173
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Cognitive Therapy
Depression
Drug Therapy
Equipment and Supplies
Randomized Controlled Trials
Odds Ratio
Demography

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression. / Vittengl, Jeffrey R.; Jarrett, Robin B.; Weitz, Erica; Hollon, Steven D.; Twisk, Jos; Cristea, Ioana; David, Daniel; DeRubeis, Robert J.; Dimidjian, Sona; Dunlop, Boadie W.; Faramarzi, Mahbobeh; Hegerl, Ulrich; Kennedy, Sidney H.; Kheirkhah, Farzan; Mergl, Roland; Miranda, Jeanne; Mohr, David C.; Rush, A. John; Segal, Zindel V.; Siddique, Juned; Simons, Anne D.; Cuijpers, Pim.

In: American Journal of Psychiatry, Vol. 173, No. 5, 01.05.2016, p. 481-490.

Research output: Contribution to journalArticle

Vittengl, JR, Jarrett, RB, Weitz, E, Hollon, SD, Twisk, J, Cristea, I, David, D, DeRubeis, RJ, Dimidjian, S, Dunlop, BW, Faramarzi, M, Hegerl, U, Kennedy, SH, Kheirkhah, F, Mergl, R, Miranda, J, Mohr, DC, Rush, AJ, Segal, ZV, Siddique, J, Simons, AD & Cuijpers, P 2016, 'Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression', American Journal of Psychiatry, vol. 173, no. 5, pp. 481-490. https://doi.org/10.1176/appi.ajp.2015.15040492
Vittengl, Jeffrey R. ; Jarrett, Robin B. ; Weitz, Erica ; Hollon, Steven D. ; Twisk, Jos ; Cristea, Ioana ; David, Daniel ; DeRubeis, Robert J. ; Dimidjian, Sona ; Dunlop, Boadie W. ; Faramarzi, Mahbobeh ; Hegerl, Ulrich ; Kennedy, Sidney H. ; Kheirkhah, Farzan ; Mergl, Roland ; Miranda, Jeanne ; Mohr, David C. ; Rush, A. John ; Segal, Zindel V. ; Siddique, Juned ; Simons, Anne D. ; Cuijpers, Pim. / Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression. In: American Journal of Psychiatry. 2016 ; Vol. 173, No. 5. pp. 481-490.
@article{484407e4cade4f4d86c027d9b2de90e0,
title = "Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression",
abstract = "Objective: Although the average depressed patient benefits moderately from cognitive-behavioral therapy (CBT) or pharmacotherapy, some experience divergent outcomes. The authors tested frequencies, predictors, and moderators of negative and unusually positive outcomes. Method: Sixteen randomized clinical trials comparing CBT and pharmacotherapy for unipolar depression in 1,700 patients provided individual pre- and posttreatment scores on the Hamilton Depression Rating Scale (HAM-D) and/or Beck Depression Inventory (BDI). The authors examined demographic and clinical predictors and treatmentmoderators of any deterioration (increase≥1HAM-Dor BDI point), reliable deterioration (increase ≥8 HAM-D or ≥9 BDI points), extreme nonresponse (posttreatment HAM-D score ≥21 or BDI score ≥31), superior improvement (HAM-D or BDI decrease≥ 95{\%}), and superior response (posttreatmentHAM-D or BDI score of 0) using multilevel models. Results: About5{\%}27{\%}of patients showedany deterioration, 1{\%} reliable deterioration, 4{\%}25{\%} extreme nonresponse, 6{\%}210{\%} superior improvement, and 4{\%}25{\%} superior response. Superior improvement on the HAM-D only (odds ratio=1.67) and attrition (odds ratio=1.67) were more frequent in pharmacotherapy than in CBT. Patients with deterioration or superior response had lower pretreatment symptom levels, whereas patients with extreme nonresponse or superior improvement had higher levels. Conclusions: Deterioration and extreme nonresponse and, similarly, superior improvement and superior response, both occur infrequently in randomized clinical trials comparing CBT and pharmacotherapy for depression. Pretreatment symptom levels help forecast negative and unusually positive outcomes but do not guide selection of CBT versus pharmacotherapy. Pharmacotherapy may produce clinician-rated superior improvement and attrition more frequently than does CBT.",
author = "Vittengl, {Jeffrey R.} and Jarrett, {Robin B.} and Erica Weitz and Hollon, {Steven D.} and Jos Twisk and Ioana Cristea and Daniel David and DeRubeis, {Robert J.} and Sona Dimidjian and Dunlop, {Boadie W.} and Mahbobeh Faramarzi and Ulrich Hegerl and Kennedy, {Sidney H.} and Farzan Kheirkhah and Roland Mergl and Jeanne Miranda and Mohr, {David C.} and Rush, {A. John} and Segal, {Zindel V.} and Juned Siddique and Simons, {Anne D.} and Pim Cuijpers",
year = "2016",
month = "5",
day = "1",
doi = "10.1176/appi.ajp.2015.15040492",
language = "English (US)",
volume = "173",
pages = "481--490",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "5",

}

TY - JOUR

T1 - Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression

AU - Vittengl, Jeffrey R.

AU - Jarrett, Robin B.

AU - Weitz, Erica

AU - Hollon, Steven D.

AU - Twisk, Jos

AU - Cristea, Ioana

AU - David, Daniel

AU - DeRubeis, Robert J.

AU - Dimidjian, Sona

AU - Dunlop, Boadie W.

AU - Faramarzi, Mahbobeh

AU - Hegerl, Ulrich

AU - Kennedy, Sidney H.

AU - Kheirkhah, Farzan

AU - Mergl, Roland

AU - Miranda, Jeanne

AU - Mohr, David C.

AU - Rush, A. John

AU - Segal, Zindel V.

AU - Siddique, Juned

AU - Simons, Anne D.

AU - Cuijpers, Pim

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Objective: Although the average depressed patient benefits moderately from cognitive-behavioral therapy (CBT) or pharmacotherapy, some experience divergent outcomes. The authors tested frequencies, predictors, and moderators of negative and unusually positive outcomes. Method: Sixteen randomized clinical trials comparing CBT and pharmacotherapy for unipolar depression in 1,700 patients provided individual pre- and posttreatment scores on the Hamilton Depression Rating Scale (HAM-D) and/or Beck Depression Inventory (BDI). The authors examined demographic and clinical predictors and treatmentmoderators of any deterioration (increase≥1HAM-Dor BDI point), reliable deterioration (increase ≥8 HAM-D or ≥9 BDI points), extreme nonresponse (posttreatment HAM-D score ≥21 or BDI score ≥31), superior improvement (HAM-D or BDI decrease≥ 95%), and superior response (posttreatmentHAM-D or BDI score of 0) using multilevel models. Results: About5%27%of patients showedany deterioration, 1% reliable deterioration, 4%25% extreme nonresponse, 6%210% superior improvement, and 4%25% superior response. Superior improvement on the HAM-D only (odds ratio=1.67) and attrition (odds ratio=1.67) were more frequent in pharmacotherapy than in CBT. Patients with deterioration or superior response had lower pretreatment symptom levels, whereas patients with extreme nonresponse or superior improvement had higher levels. Conclusions: Deterioration and extreme nonresponse and, similarly, superior improvement and superior response, both occur infrequently in randomized clinical trials comparing CBT and pharmacotherapy for depression. Pretreatment symptom levels help forecast negative and unusually positive outcomes but do not guide selection of CBT versus pharmacotherapy. Pharmacotherapy may produce clinician-rated superior improvement and attrition more frequently than does CBT.

AB - Objective: Although the average depressed patient benefits moderately from cognitive-behavioral therapy (CBT) or pharmacotherapy, some experience divergent outcomes. The authors tested frequencies, predictors, and moderators of negative and unusually positive outcomes. Method: Sixteen randomized clinical trials comparing CBT and pharmacotherapy for unipolar depression in 1,700 patients provided individual pre- and posttreatment scores on the Hamilton Depression Rating Scale (HAM-D) and/or Beck Depression Inventory (BDI). The authors examined demographic and clinical predictors and treatmentmoderators of any deterioration (increase≥1HAM-Dor BDI point), reliable deterioration (increase ≥8 HAM-D or ≥9 BDI points), extreme nonresponse (posttreatment HAM-D score ≥21 or BDI score ≥31), superior improvement (HAM-D or BDI decrease≥ 95%), and superior response (posttreatmentHAM-D or BDI score of 0) using multilevel models. Results: About5%27%of patients showedany deterioration, 1% reliable deterioration, 4%25% extreme nonresponse, 6%210% superior improvement, and 4%25% superior response. Superior improvement on the HAM-D only (odds ratio=1.67) and attrition (odds ratio=1.67) were more frequent in pharmacotherapy than in CBT. Patients with deterioration or superior response had lower pretreatment symptom levels, whereas patients with extreme nonresponse or superior improvement had higher levels. Conclusions: Deterioration and extreme nonresponse and, similarly, superior improvement and superior response, both occur infrequently in randomized clinical trials comparing CBT and pharmacotherapy for depression. Pretreatment symptom levels help forecast negative and unusually positive outcomes but do not guide selection of CBT versus pharmacotherapy. Pharmacotherapy may produce clinician-rated superior improvement and attrition more frequently than does CBT.

UR - http://www.scopus.com/inward/record.url?scp=84965150449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965150449&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2015.15040492

DO - 10.1176/appi.ajp.2015.15040492

M3 - Article

VL - 173

SP - 481

EP - 490

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 5

ER -